Matthew Norton has over a decade of experience in the healthcare investment sector, currently serving as a Partner at Cinven since February 2010. In addition to this role, Matthew holds several non-executive director positions, including with BioAgilytix, LGC, and STADA Group, where involvement includes oversight of Nidda Healthcare, a major shareholder of Stada Arzneimittel AG. Previous experience includes a non-executive director role at Medpace and M&A at Citi from 2007 to 2010. Matthew holds an MSci in Physics from Imperial College London, obtained in 2007, and attended Haberdashers' Boys' School for earlier education.